<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4934">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03620409</url>
  </required_header>
  <id_info>
    <org_study_id>ZKSJ106-V1.3</org_study_id>
    <secondary_id>DRKS00013347</secondary_id>
    <nct_id>NCT03620409</nct_id>
  </id_info>
  <brief_title>Identification of Cardiovascular and Molecular Prognostic Factors for the Mid- and Long-term Outcome of Sepsis</brief_title>
  <acronym>ICROS</acronym>
  <official_title>Identification of Cardiovascular and Molecular Prognostic Factors for the Mid- and Long-term Outcome of Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jena University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Anesthesiology and Intensive Care Medicine, JUH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Cardiothoracic Surgery, JUH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Clinical Chemistry and Laboratory Medicine, JUH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Biochemistry, Center for Molecular Biomedicine (CMB), FSU Jena</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Systems Biology and Bioinformatics, Hans-Kn√∂ll Institute Jena</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Pharmacy, FSU Jena</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jena University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sepsis is a life-threatening condition which can affect people of any age. An infection&#xD;
      triggers a host response resulting in organ failure. The extent of the organ dysfunction&#xD;
      varies between patients and during the course of the condition. Thus far, the only causal&#xD;
      treatment option consists in treating the infection early e. g. by an operation or the use of&#xD;
      antibiotics. Owing to advances in modern critical care, more patients survive sepsis.&#xD;
      Nonetheless, sepsis survivors frequently show impaired organ function, physical disability&#xD;
      and considerably decreased health-related quality of life.&#xD;
&#xD;
      It is hypothesized that sepsis-induced cardiac dysfunction - septic cardiomyopathy - may&#xD;
      influence mortality. The relationship between occurrence of cardiovascular dysfunction and&#xD;
      metabolic changes in the course of sepsis remains unclear. Therefore, the aim of this study&#xD;
      is the investigation of cardiovascular function, oxygen consumption and metabolic changes in&#xD;
      septic patients. Apart from cardiological routine procedures (echo- and electrocardiography)&#xD;
      a newly developed method for measuring the oxygen tension and consumption, bioelectrical&#xD;
      impedance analysis for body composition estimation and liver fibrosis assessment via&#xD;
      transient elastography will be employed. Through blood, stool and urine analysis, both&#xD;
      routine parameters and parameters focusing on patient metabolism will be analysed.&#xD;
&#xD;
      Septic patients will be assessed in the acute phase (3 and 7 days after sepsis diagnosis),&#xD;
      the stable phase (at intensive care unit discharge) and after full or incomplete recovery&#xD;
      (during two outpatient visits at 6 and 12 months after sepsis diagnosis). The results will be&#xD;
      compared with healthy individuals and patients with existing heart disease (cardiomyopathy).&#xD;
&#xD;
      The study aims to identify clinical parameters and signaling pathways involved in the&#xD;
      development and course of sepsis. Furthermore, specific parameters associated with the&#xD;
      medium- and long-term health status, physical performance and quality of life after sepsis&#xD;
      are to be identified. The overall aim of the study is the development of novel diagnostic and&#xD;
      therapeutic approaches in sepsis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall aim of the study is the identification of theragnostic targets for the&#xD;
      development of novel diagnostic and therapeutic approaches in sepsis. In sepsis, a&#xD;
      dysregulated host response to infection leads to organ failure. The extent of organ&#xD;
      dysfunction varies between patients and at different stages of the disease. Advances in&#xD;
      modern critical care have reduced 28-day mortality over the last years. Nonetheless, a large&#xD;
      proportion of sepsis survivors reports long-term physical, mental and cognitive impairments&#xD;
      (post intensive care syndrome) including persistent organ dysfunction (persistent critical&#xD;
      illness). In addition, mortality rates are considerably increased up to years after sepsis.&#xD;
      However, the underlying molecular mechanisms remain unclear.&#xD;
&#xD;
      There is evidence that the development of septic cardiomyopathy may influence mortality. The&#xD;
      relationship between the occurrence of cardiovascular dysfunction and metabolic changes in&#xD;
      the course of sepsis has not yet been investigated. Therefore, the key aim of this study is&#xD;
      the investigation of cardiovascular function, oxygen consumption and metabolic changes in&#xD;
      septic patients. Apart from cardiological routine procedures (echo- and electrocardiography)&#xD;
      a newly developed method for measuring the mitochondrial oxygen tension and consumption&#xD;
      (COMET) will be applied. As oedema is involved in the pathogenesis of altered&#xD;
      microcirculation in sepsis, endothelial dysfunction will be analysed via a set of surrogate&#xD;
      parameters and body composition (especially extracellular water) measurement via&#xD;
      bioelectrical impedance analysis. Liver fibrosis will be assessed via transient elastography.&#xD;
      In blood, stool and urine, routine parameters and the metabolome, lipidome and microbiome&#xD;
      will be analysed. Septic patients will be assessed in the acute phase (3 and 7 days after&#xD;
      sepsis diagnosis), the stable phase (at intensive care unit discharge) and after full or&#xD;
      incomplete recovery (during two outpatient visits at 6 and 12 months sepsis diagnosis).&#xD;
      Analyses will be complemented by in-depth anamnestic and clinical-epidemiological assessment&#xD;
      as well as subsequent information on health related quality of life (EQ-5D-3L) and physical&#xD;
      performance (6-minute walk test).&#xD;
&#xD;
      The primary endpoint of the study is the difference in mortality rates between septic&#xD;
      patients with and without septic cardiomyopathy six months after sepsis diagnosis. Further&#xD;
      research questions include differences in clinical and laboratory parameters between these&#xD;
      patient groups during the acute phase, and during the mid-, and long-term course.&#xD;
&#xD;
      The results will be compared with healthy individuals and patients with cardiomyopathy in&#xD;
      absence of infection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2018</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality differences between septic patients with vs. without septic cardiomyopathy six months after sepsis diagnosis</measure>
    <time_frame>Six months after sepsis diagnosis</time_frame>
    <description>Difference in mortality rates between septic patients with vs. without septic cardiomyopathy six months after sepsis diagnosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality differences between septic patients with vs. without septic cardiomyopathy twelve months after sepsis diagnosis</measure>
    <time_frame>Twelve months after sepsis diagnosis</time_frame>
    <description>Difference in mortality rates between septic patients with vs. without septic cardiomyopathy twelve months after sepsis diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of septic cardiomyopathy</measure>
    <time_frame>from enrollment until 3 days after ICU discharge</time_frame>
    <description>Estimation of incidence of septic cardiomyopathy in the acute phase of sepsis</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">290</enrollment>
  <condition>Sepsis</condition>
  <condition>Septic Cardiomyopathy</condition>
  <condition>Cardiomyopathies</condition>
  <arm_group>
    <arm_group_label>Sepsis</arm_group_label>
    <description>Patients with and without diagnosis septic cardiomyopathy Patients with and without suspected or confirmed SARS-CoV-2 infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cardiomyopathy without infection</arm_group_label>
    <description>Patients without operation and patients with scheduled LVAD-Implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects</arm_group_label>
    <description>Healthy controls</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, urine and stool samples.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        primary care and community sample&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients with Sepsis:&#xD;
&#xD;
          -  sepsis or septic shock according to Sepsis-3 criteria&#xD;
&#xD;
          -  first infection-associated organ dysfunction (= sepsis diagnosis) no older than 72&#xD;
             hours (first blood sample within 96 hours after sepsis diagnosis)&#xD;
&#xD;
          -  written informed consent of the patient or his legal representative&#xD;
&#xD;
        Patients with cardiomyopathy without inflammation:&#xD;
&#xD;
          -  cardiomyopathy without inflammation&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
        Healthy subjects:&#xD;
&#xD;
        - written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients with sepsis:&#xD;
&#xD;
          -  cardiac surgery ‚â§ 12 months&#xD;
&#xD;
          -  sepsis/septic shock ‚â§ 8 months&#xD;
&#xD;
          -  significant pre-existing heart condition&#xD;
&#xD;
               -  endocarditis&#xD;
&#xD;
               -  higher-grade valvular heart disease (grade 3 valve disease, symptomatic aortic&#xD;
                  stenosis, medium-degree mitral valve insufficiency with reduced ejection fraction&#xD;
                  or clinical symptoms)&#xD;
&#xD;
               -  complex structural congenital heart disorders (e.g. TGA, Fallot-Tetralogie,&#xD;
                  endocardial cushion defect)&#xD;
&#xD;
               -  pre-existing significantly reduced cardiac performance (ejection fraction &lt; 45 %&#xD;
                  or 10 % below norm value)&#xD;
&#xD;
               -  pre-existing pulmonary hypertension&#xD;
&#xD;
               -  myocardial infarction ‚â§ 1 year in patient history&#xD;
&#xD;
               -  heart transplantation in patient history&#xD;
&#xD;
               -  permanent atrial fibrillation&#xD;
&#xD;
          -  pneumectomy in medical history&#xD;
&#xD;
          -  contraindication for transesophageal echocardiography (e.g. esophageal resection,&#xD;
             higher-grade esophagus varices) and insufficient sonography conditions for&#xD;
             transthoracic echocardiography&#xD;
&#xD;
          -  liver cirrhosis Child C&#xD;
&#xD;
          -  terminal kidney disease with dialysis&#xD;
&#xD;
          -  pregnancy/breastfeeding&#xD;
&#xD;
          -  previous participation in this study&#xD;
&#xD;
          -  participation in another intervention study&#xD;
&#xD;
          -  therapy limitation, DNR / DNI order&#xD;
&#xD;
          -  life expectancy ‚â§ 6 months due to comorbidities&#xD;
&#xD;
          -  cardiopulmonary resuscitation &lt; 4 weeks before onset of sepsis&#xD;
&#xD;
        Patients with cardiomyopathy without infection:&#xD;
&#xD;
          -  sepsis/septic shock ‚â§ 8 months&#xD;
&#xD;
          -  acute organ failure (except cardiac decompensation/cardiogenic shock due to dilated&#xD;
             cardiomyopathy) ‚â§ 6 months due to infection&#xD;
&#xD;
          -  complex structural congenital heart disorders (e.g. TGA, Fallot-Tetralogie,&#xD;
             endocardial cushion defect)&#xD;
&#xD;
          -  infection at point of inclusion&#xD;
&#xD;
          -  cardiogenic shock at point of inclusion&#xD;
&#xD;
          -  heart transplantation in medical history&#xD;
&#xD;
          -  mechanical heart assist device&#xD;
&#xD;
          -  pneumonectomy in medical history&#xD;
&#xD;
          -  liver cirrhosis Child C&#xD;
&#xD;
          -  terminal kidney disease with dialysis&#xD;
&#xD;
          -  contraindication for transesophageal echocardiography (e.g. esophageal resection,&#xD;
             higher-grade esophagus varices) and insufficient sonographic conditions for&#xD;
             transthoracic echocardiography&#xD;
&#xD;
          -  pregnancy/breastfeeding&#xD;
&#xD;
          -  therapy limitation / DNR / DNI order&#xD;
&#xD;
          -  life expectancy ‚â§ 6 months due to comorbidities&#xD;
&#xD;
          -  previous participation in this study&#xD;
&#xD;
          -  participation in another interventional study&#xD;
&#xD;
          -  cardiopulmonary resuscitation &lt; 4 weeks&#xD;
&#xD;
        Healthy subjects:&#xD;
&#xD;
          -  sepsis/septic shock ‚â§ 8 months&#xD;
&#xD;
          -  ICU treatment ‚â§ 6 months&#xD;
&#xD;
          -  infection at point of inclusion&#xD;
&#xD;
          -  heart surgery (including heart transplantation) in medical history&#xD;
&#xD;
          -  significant pre-existing cardiac condition&#xD;
&#xD;
               -  higher-degree valvular heart disease (grade 3 valve disease, symptomatic aortic&#xD;
                  stenosis, medium-degree mitral valve insufficiency with reduced ejection fraction&#xD;
                  or clinical symptoms)&#xD;
&#xD;
               -  complex structural congenital heart disorders (e.g. TGA, Fallot-Tetralogie,&#xD;
                  endocardial cushion defect)&#xD;
&#xD;
               -  pre-existing significantly reduced cardiac performance (ejection fraction &lt; 45 %&#xD;
                  or 10 % below norm value)&#xD;
&#xD;
               -  pre-existing pulmonary hypertension&#xD;
&#xD;
               -  myocardial infarction ‚â§ 1 year in medical history&#xD;
&#xD;
          -  pneumonectomy in medical history&#xD;
&#xD;
          -  liver cirrhosis Child C&#xD;
&#xD;
          -  terminal kidney disease with dialysis&#xD;
&#xD;
          -  contraindication for transesophageal echocardiography (e.g. esophageal resection,&#xD;
             higher-grade esophagus varices) and insufficient sonography conditions for&#xD;
             transthoracic echocardiography&#xD;
&#xD;
          -  pregnancy/breastfeeding&#xD;
&#xD;
          -  life expectancy ‚â§ 6 months due to comorbidities&#xD;
&#xD;
          -  previous participation in this study&#xD;
&#xD;
          -  participation in another intervention study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sina M Coldewey, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sina M Coldewey, MD, PhD</last_name>
    <phone>+4936419323101</phone>
    <email>Sina.Coldewey@med.uni-jena.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charles Neu, MD</last_name>
    <phone>+4936419323101</phone>
    <email>charles.neu@med.uni-jena.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NWG Translational Septomics, Zentrum f√ºr Innovationskomepetenz (ZIK) Septomics, Universit√§tklinikum Jena</name>
      <address>
        <city>Jena</city>
        <state>Thuringia</state>
        <zip>D-07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sina M Coldewey, MD, PhD</last_name>
      <phone>+4936419323101</phone>
      <email>sina.coldewey@med.uni-jena.de</email>
    </contact>
    <contact_backup>
      <last_name>Charles Neu, MD</last_name>
      <phone>4936419323101</phone>
      <email>charles.neu@med.uni-jena.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.septomics.de/en/translational-septomics.html</url>
    <description>Homepage</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 15, 2018</study_first_submitted>
  <study_first_submitted_qc>August 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2018</study_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jena University Hospital</investigator_affiliation>
    <investigator_full_name>Sina Coldewey</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

